文献速递特殊人群用药治疗药物监测与药物基因组学药物不良反应与药物警戒

生理药代动力学模型预测妊娠期阿米替林药代动力学改变

Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy.
PubMed 文献 · Br J Clin Pharmacol · 2025-05-01

该研究利用PBPK模型模拟妊娠期阿米替林及其活性代谢物去甲替林的药代动力学变化,并与临床常规监测浓度比较。结果显示妊娠期阿米替林活性部分总浓度不变,但阿米替林浓度升高而去甲替林浓度降低。建议临床关注耐受性变化并开展治疗药物监测。

要点

  • 妊娠期阿米替林活性部分总浓度与孕前相当,但阿米替林浓度升高、去甲替林浓度降低。
  • 阿米替林浓度升高可能增加抗胆碱能效应,影响耐受性。
  • 建议妊娠期监测阿米替林血清浓度以降低停药风险。

核心结论

  • 妊娠期阿米替林活性部分总浓度不变,但阿米替林浓度升高而去甲替林浓度降低。

研究设计与样本

  • 开发包含阿米替林和去甲替林的PBPK模型(PK-Sim 11版),预测妊娠期药代动力学变化并与临床常规监测浓度比较。

主要发现

  • 模型成功描述血清浓度曲线;妊娠期阿米替林活性部分总浓度不变,阿米替林浓度升高,去甲替林浓度降低。

临床怎么用

  • 医生应知晓妊娠期阿米替林浓度升高可能增加抗胆碱能效应,建议进行治疗药物监测尤其监测阿米替林血清浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmacotherapy of maternal peripartum depression is an increasing challenge. Amitriptyline (AMI) is the most often used tricyclic antidepressant during pregnancy, but knowledge on pharmacokinetics in this special phase is lacking. Physiologically based pharmacokinetic (PBPK) modelling is a powerful tool to better understand pregnancy-induced pharmacokinetic changes of medication. We aimed to improve the knowledge about AMI pharmacokinetics during pregnancy using PBPK modelling. Consequently, we aimed to add new information for an effective and safe pharmacotherapy in pregnant women. METHODS: A PBPK model, including AMI, but also its active metabolite nortriptyline (NOR), was developed to investigate pregnancy-induced pharmacokinetic changes after AMI administration. The predicted drug exposure was compared to observed concentrations in pregnant patients in clinical routine. The PBPK model was set up using PK-Sim Version 11. RESULTS: Serum concentration profiles were described successfully. During pregnancy, active moiety serum concentration of AMI (AMI + NOR) did not change; however, AMI concentration increased, whereas NOR concentration decreased. CONCLUSIONS: With this model, we added valuable information on AMI pharmacokinetics during pregnancy (increased AMI concentration, decreased NOR concentration). For clinical practice the treating physician should be aware that despite active moiety serum concentration comparable to before pregnancy, tolerability may be affected due to increased AMI serum concentrations and as consequence increased anticholinergic effects. To keep the risk of therapy discontinuation during pregnancy low, we suggest performing therapeutic drug monitoring, especially to check the AMI serum concentration.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Scherf-Clavel M, Leutritz AL, Gehrmann A, et al. Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy. Br J Clin Pharmacol. 2025. PMID: 40312020. doi:10.1002/bcp.70084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。